Drug Overview
AstraZeneca’s Symbicort ([budesonide + formoterol]) was the second inhaled corticosteroid/long-acting beta 2 agonist (ICS/LABA) drug combination to launch on the respiratory market, starting with approval for asthma. This was followed by approval for chronic obstructive pulmonary disease in the EU in 2003 and in the US in February 2009. In Japan, where Symbicort is co-promoted by Astellas and AstraZeneca, the drug received approval in August 2012. Budesonide is an ICS that exhibits potent glucocorticoid activity, and formoterol is a LABA that acts locally in the lungs as a bronchodilator.
AstraZeneca’s Symbicort ([budesonide + formoterol]) was the second inhaled corticosteroid/long-acting beta 2 agonist (ICS/LABA) drug combination to launch on the respiratory market, starting with approval for asthma. This was followed by approval for chronic obstructive pulmonary disease in the EU in 2003 and in the US in February 2009. In Japan, where Symbicort is co-promoted by Astellas and AstraZeneca, the drug received approval in August 2012. Budesonide is an ICS that exhibits potent glucocorticoid activity, and formoterol is a LABA that acts locally in the lungs as a bronchodilator.
Table of Contents
OVERVIEW
LIST OF FIGURES
LIST OF TABLES